Cable Hill Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Cable Hill Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-86	Closed	-$4K	–	837
2019 Q1	$4K	Hold	86	–	–	﹤0.01%	688
2018 Q4	$3K	Hold	86	–	–	﹤0.01%	693
2018 Q3	$3K	Sell	86 -15	-15%	-$552	﹤0.01%	696
2018 Q2	$4K	Hold	101	–	–	﹤0.01%	756
2018 Q1	$2K	Sell	101 -192	-66%	-$5.74K	﹤0.01%	848
2017 Q4	$8K	Hold	293	–	–	﹤0.01%	641
2017 Q3	$11K	Buy	+293	New	+$8.89K	0.01%	564

Other funds holding BHVN

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RP Management New York $139M AUM 37.98% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cable Hill Partners's BHVN Position: Q2 2019 in Review

Cable Hill Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2019, closing a stake of 86 shares — an estimated $4K sold.

Cable Hill Partners first reported a position in BHVN in Q3 2017 and held it in 7 quarters. The position peaked at $11K in Q3 2017. 197 funds tracked by Wall St. Rank hold BHVN as of Q2 2019.

Cable Hill Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2019 after selling out during the quarter.
Cable Hill Partners sold 86 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2019, an estimated $4K.
Cable Hill Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2017 and held it in 7 quarters.
Cable Hill Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $11K in Q3 2017.
197 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2019.

Based on Cable Hill Partners's 13F filing for Q2 2019, filed 6 Aug 2019.